Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Autoimmune Vision Loss Panel, Serum

3016804

Autoimmune Vision Loss Panel, Serum 3016804

Method

Qualitative Immunoblot/Semi-Quantitative Cell-Based Indirect Fluorescent Antibody

Disease Overview

Vision loss may be a symptom of many conditions, including paraneoplastic autoimmune neurologic diseases such as cancer-associated retinopathy and paraneoplastic optic neuropathy. While these diseases are less common than vision loss due to optic neuritis (as seen in multiple sclerosis and neuromyelitis optica spectrum disorders), including them in the differential for vision loss has important implications for cancer screening and treatment.

For more information about the testing strategy for the following conditions, refer to ARUP Consult topics:

Test Description

Consider this phenotype-targeted panel for the evaluation of a subacute onset of progressive bilateral vision loss when there is concern for a paraneoplastic autoimmune etiology.

This panel includes antibodies associated with paraneoplastic vision loss; if there is concern for demyelinating disease, consider the Autoimmune CNS Demyelinating Disease Reflexive Panel, which includes AQP4 and MOG antibodies. To compare these panels and the antibodies included, refer to ARUP Autoimmune Neurology Panel Components. Testing for individual antibodies is also available separately.

Antibodies Tested and Methodology

Autoimmune Vision Loss Panel, Serum (3016804): Antibodies Tested and Methodology
	Methodology	Individual Autoantibody Test Code
CV2 (CRMP-5) Ab, IgG	CBA-IFA	3016999
Recoverin Ab, IgG	IB	3016794
Ab, antibody; CBA, cell-binding assay/cell-based assay; CRMP-5, collapsin response-mediator protein 5; IB, immunoblot; IFA, indirect immunofluorescence assay; IgG, immunoglobulin G

Reflex Patterns

Reflex pattern for Autoimmune Vision Loss Panel, Serum (3016804)

Limitations

This panel does not include every antibody that has been associated with autoimmune vision loss. As testing for newly described antibodies becomes available and their clinical relevance is established, this panel will evolve to reflect these discoveries.

Test Interpretation

Results

Results should be interpreted in the context of the patient’s clinical history, neurologic and ophthalmologic exam, and other laboratory findings. Test results (positive or negative) should not supersede clinical judgment.

Autoimmune Vision Loss Panel, Serum (3016804): Results Interpretation
Result	Interpretation
Positive for ≥1 autoantibodies	Autoantibody(ies) detected Supports a clinical diagnosis of autoimmune vision loss Consider a focused search for malignancy based on established antibody-tumor associations
Negative	No autoantibodies detected A diagnosis of autoimmune vision loss is not excluded

References

27112687

Petzold A, Wong S, Plant GT. Autoimmunity in visual loss. Handb Clin Neurol. 2016;133:353-376.

37282453

Wang S, Hou H, Tang Y, et al. An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes. Neural Regen Res. 2023;18(11):2357-2364.

Feedback